[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366646-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366646-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-a-free-n-glycan-with-difucosylated-type-1-lactosamine-in-cancerous-tissue-and-its-validation-for-cancer-diagnosis-by-urinary-testing","Identification of a free-N-glycan with difucosylated type-1 lactosamine in cancerous tissue and its validation for cancer diagnosis by urinary testing","","Numerous urinary acidic free-glycan tumor marker candidates have been proposed from glycan profiles of human cancers. This study identifies a novel neutral free-glycan elevated in colorectal cancer cells versus normal epithelium, characterized as a free-N-glycan bearing a difucosylated type-1 lactosamine (Lewis B antigen). Type-1 lactosamine N-glycans are rarely reported in humans. Clinical utility was assessed by measuring urinary levels in healthy subjects and multiple cancer cohorts using liquid chromatography-selected reaction monitoring. Significant differences supported potential diagnostic value.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-a-free-n-glycan-with-difucosylated-type-1-lactosamine-in-cancerous-tissue-and-its-validation-for-cancer-diagnosis-by-urinary-testing/366646/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-a-free-n-glycan-with-difucosylated-type-1-lactosamine-in-cancerous-tissue-and-its-validation-for-cancer-diagnosis-by-urinary-testing/366646.png","ImageObject",300,407,{"name":42,"@type":43},"Bulrr","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What free-glycan was found to be significantly elevated in colorectal cancer cells?","Question",{"text":63,"@type":64},"A neutral free-N-glycan was detected as markedly elevated in colorectal cancer cells compared with corresponding normal epithelial cells. Structural studies identified it as a difucosylated type-1 lactosamine (Lewis B antigen).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the clinical usefulness of this glycan evaluated?",{"text":68,"@type":64},"The study measured the free-glycan level in urine using a liquid chromatography-selected reaction monitoring assay. The cohorts included healthy subjects and multiple cancer patient groups.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is there an urgent need for novel tumor markers?",{"text":72,"@type":64},"Some patients do not show elevations in existing markers, CA19-9 is not usable for individuals with Lewis enzyme deficiency, and early-stage cancers are often not detected. These limitations drive the need for new biomarkers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366646,1790879919,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIdentification of a free-N-glycan with difucosylated type-1 lactosamine in cancerous tissue and its validation for cancer diagnosis by urinary testing  \nMiki Tanaka-Okamoto1, Ken Hanzawa2, Takashi Yamamoto3, Kazuyoshi Ohkawa4, Ken-ichi Yoshida5, Satoshi Takenaka6, Masayuki Ohue7, Tomoyuki Yamasaki3 & Yasuhide Miyamoto3􀀍  \nNumerous urinary acidic free-glycan tumor marker candidates have been identified based on the glycan structure profiles of human cancer tissues. In this study, to identify novel glycan tumor markers, we performed precise glycan structural analysis focusing on neutral free-glycans in colorectal cancer tissues. Our analysis detected one free-glycan that was significantly elevated in colorectal cancer cells by comparison to the corresponding normal epithelial cells. Structural studies of this glycan revealed it to comprise a free-N-glycan with a difucosylated type-1 lactosamine structure (Lewis B antigen), rather than a conventional type-2 lactosamine structure. The presence of N-glycans with type-1 lactosamine structure has rarely been reported in humans. To investigate its clinical usefulness, the level of this free-glycan in the urine of 121 healthy subjects, 141 gastric cancer patients, 87 colorectal cancer patients, 55 pancreatic cancer patients, 13 bile duct cancer patients and 79 rare cancer patients were measured using a liquid chromatography-selected reaction monitoring assay. Significant differences were detected in cancer patient samples compared to healthy controls, with a marked increase in some rare-types of cancer patient samples, such asAFP-producing gastric cancer.  \nKeywords Free-glycan, Mass spectrometry, Tumor marker, Urine  \nLiquid biopsy is a means of capturing heterogeneity within cancers. Significant research effort is focused on searching for tumor biomarkers in biological fluids that are less invasive. Blood markers currently in clinical use include α-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), which are used to confirm treatment efficacy and monitor cancer recurrence. The most frequently used tumor marker, mainly for pancreatic cancer, is CA19-9, which is detected as a cancer antigen by antibodies that recognize the altered glycan structure sialyl Lewis A on the cancer cell membrane1,2. AFP, which is used to monitor the development of hepatocellular carcinoma, has been reported to have oncogenic glycan mutations and its cancer specificity is increased as fucosylated AFP (AFP-L3)3,4. Thus, aberrant glycan structures on cancer cells have been used for cancer detection and can act as valuable diagnostic tools in clinical practice. However, there are many cancer patients for whom existing tumor markers are not elevated. CA19-9 cannot be used as a tumor marker in people with a deficiency of Lewis enzyme, which is the enzyme that synthesizes its target glycan structure. Additionally, certain individuals might be incorrectly identified as positive cases. Furthermore, most markers are unable to detect early-stage cancer. Therefore, there is an urgent need to develop novel markers.  \n1Department of Glyco-Oncology and Medical Biochemistry, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka 541-8567, Japan. 2Glycoanalytical Chemistry Lab, Institute for Glyco-Core Research (iGCORE), Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan. 3Department of Clinical Laboratory, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka 541-8567, Japan. 4Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka 541-8567, Japan. 5Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka 541- 8567, Japan. 6Department of Orthopedic Surgery, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka 541-8567, Japan. 7Department of ","cbCaimOP4OuGfyOl","https://ap.wps.com/l/cbCaimOP4OuGfyOl","pdf",1515440,"English","# Introduction\n## Liquid biopsy and tumor biomarkers in biological fluids\n## Need for novel glycan-based markers\n# Methods and Glycan Analysis Approach\n## Structural analysis in colorectal cancer tissues\n## LC-SRM measurement in urine cohorts\n# Results and Clinical Validation\n## Elevated free-glycan in colorectal cancer cells\n## Differences across cancer types\n# Background and Rationale\n## Glycan alterations and glycomics strategies","[{\"question\":\"What free-glycan was found to be significantly elevated in colorectal cancer cells?\",\"answer\":\"A neutral free-N-glycan was detected as markedly elevated in colorectal cancer cells compared with corresponding normal epithelial cells. Structural studies identified it as a difucosylated type-1 lactosamine (Lewis B antigen).\"},{\"question\":\"How was the clinical usefulness of this glycan evaluated?\",\"answer\":\"The study measured the free-glycan level in urine using a liquid chromatography-selected reaction monitoring assay. The cohorts included healthy subjects and multiple cancer patient groups.\"},{\"question\":\"Why is there an urgent need for novel tumor markers?\",\"answer\":\"Some patients do not show elevations in existing markers, CA19-9 is not usable for individuals with Lewis enzyme deficiency, and early-stage cancers are often not detected. These limitations drive the need for new biomarkers.\"}]","Identification of a free-N-glycan with difucosylated type-1 lactosamine in cancerous tissue and its validation for cancer diagnosis by urinary testing | PDF",1790166557,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3267cdacad479da56ae39effe754a8c3.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/132ce479b74231e9d19cdb931677fc6a.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d8131eaa5dcd9bc30a2b9496add61f8.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c6051719835c20ba99969bb76569e17.webp",980,1287]